Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prediction Model of Avastin Plus Chemotherapy as First Line Treatment in Unresectable Ras Mutant Colorectal Liver Metastase (CRLM) Patients

NCT04525313 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04525313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04525313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prediction Model of Avastin Plus Chemotherapy as First Line Treatment in Unresectable Ras Mutant Colorectal Liver Metastase (CRLM) Patients
Lead sponsor
Fudan University
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2020
Completion date
December 31, 2022
Enrollment
116 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, liver metastases